Brain-targeted Brivaracetam delivery using mannose-functionalized mesoporous silica nanoparticles for the treatment of epilepsy
Brain Research · 2026-06 · 1880 · 150252
DOI: 10.1016/j.brainres.2026.150252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Research, 2026-06. Verfasst von Sumit Patel und 3 weiteren Autor:innen. Beteiligte Einrichtung: L. M. College of Pharmacy, Opposite Gujarat University, Navrangpura, Ahmedabad, Gujarat 380009, India. Hauptthemen laut MEDLINE: Pyrrolidinones, Nanoparticles, Anticonvulsants, Brain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Abstract (Originalsprache)
Surface-engineered mesoporous silica nanoparticles (MSN) as carrier system for controlled release of Brivaracetam (BVM) for targeted brain delivery in epilepsy were developed and evaluated. Modified sol-gel process employed to synthesize MSN using tetraethylorthosilicate (TEOS) as silica source and cetyltrimethylammonium bromide (CTAB) as structure-directing agent, followed by calcination. Surface functionalization was achieved by grafting aminopropyl triethoxysilane (APTES) to introduce amine groups. Surface modification was carried out by amination, followed by the conjugation of D-mannose. Physical adsorption method was used to incorporate BVM into MSN. In-vitro studies revealed that BVM solution released 96.11% of drug within 5 h, while MSN formulation extended release upto 98.13% over 24 h. 94.25% of the drug release was observed from mannose-conjugated amine MSN over 48 h, aligning with Korsmeyer-Peppas model. Maximal Electroshock seizures (MES) model used for In-vivo pharmacodynamic evaluation, indicated that untreated group experienced 16.25 ± 1.11 seizure episodes (absence of treatment). BVM loaded MSN treatment reduced to 13.25 ± 1.11 episodes (69.63% antiepileptic effect), while mannose-conjugated BVM-loaded MSN group further decreased to 12.5 ± 1.32 episodes (71.42% antiepileptic activity). These results suggest that surface functionalized MSN are promising for sustained drug delivery for improved seizure control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- L. M. College of Pharmacy, Opposite Gujarat University, Navrangpura, Ahmedabad, Gujarat 380009, India.
- L. M. College of Pharmacy, Opposite Gujarat University, Navrangpura, Ahmedabad, Gujarat 380009, India. Electronic address: mansi.athalye@lmcp.ac.in.
Zitieren
APA
Patel, S., Mansuri, M., Mehta, I., & Athalye, M. (2026). Brain-targeted Brivaracetam delivery using mannose-functionalized mesoporous silica nanoparticles for the treatment of epilepsy. Brain Research, 1880, 150252. https://doi.org/10.1016/j.brainres.2026.150252
Vancouver
Patel S, Mansuri M, Mehta I, Athalye M. Brain-targeted Brivaracetam delivery using mannose-functionalized mesoporous silica nanoparticles for the treatment of epilepsy. Brain Research. 2026;1880:150252. doi:10.1016/j.brainres.2026.150252
BibTeX
@article{Patel2026,
author = {Patel, Sumit and Mansuri, Mustakim and Mehta, Ishani and Athalye, Mansi},
title = {Brain-targeted Brivaracetam delivery using mannose-functionalized mesoporous silica nanoparticles for the treatment of epilepsy},
journal = {Brain Research},
year = {2026},
volume = {1880},
pages = {150252},
doi = {10.1016/j.brainres.2026.150252}
}
EUVIMED